Dr James Dale

  • Honorary Clinical Senior Lecturer (Institute of Infection Immunity & Inflammation)

email: James.Dale@glasgow.ac.uk

Department of Rheumatology, Univeristy Hospital Wishaw, Netherton Road, Wishaw, ML2 0DP

Publications

List by: Type | Date

Jump to: 2021 | 2020 | 2016 | 2015 | 2014 | 2012 | 2010
Number of items: 11.

2021

Derakhshan, M. H., Morton, F., Fragoulis, G. E., Paterson, C., Dale, J., Basu, N. , Mcinnes, I., Porter, D. and Siebert, S. (2021) Opioids and analgesic use in early rheumatoid arthritis: a longitudinal analysis of linked real-world prescription data. Annals of the Rheumatic Diseases 80(S1): 1159. EULAR 2021 Virtual Congress., 2-5 June 2021. (doi:10.1136/annrheumdis-2021-eular.2672)

2020

Daly, R. et al. (2020) Changes in plasma itaconate elevation in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation. Metabolites, 10(6), 241. (doi: 10.3390/metabo10060241) (PMID:32531990) (PMCID:PMC7344783)

2016

Dale, J. et al. (2016) The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 17, 461. (doi: 10.1186/s12891-016-1318-y) (PMID:27829394) (PMCID:PMC5103386)

Kronisch, C. et al. (2016) Brief report: predicting functional disability: one-year results from the Scottish Early Rheumatoid Arthritis inception cohort. Arthritis and Rheumatology, 68(7), pp. 1596-1602. (doi: 10.1002/art.39627) (PMID:26866516)

Porter, D. et al. (2016) Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet, 388(10041), pp. 239-247. (doi: 10.1016/S0140-6736(16)00380-9) (PMID:27197690)

Dale, J. et al. (2016) Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Annals of the Rheumatic Diseases, 75(6), pp. 1043-1050. (doi: 10.1136/annrheumdis-2015-208941) (PMID:27026689)

2015

Dale, J. (2015) Advances in the management of rheumatoid arthritis. Scottish Medical Journal, 60(3), pp. 108-114. (doi: 10.1177/0036933015592761) (PMID:26122283)

2014

Dale, J., Purves, D., McConnachie, A. , McInnes, I. and Porter, D. (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care and Research, 66(1), pp. 19-26. (doi: 10.1002/acr.22218)

Porter, D., Dale, J. and Sattar, N. (2014) How low to aim in rheumatoid arthritis? Learning from other disciplines. Annals of the Rheumatic Diseases, 73(3), pp. 480-482. (doi: 10.1136/annrheumdis-2013-204339)

2012

Crilly, A. et al. (2012) PAR2 expression in peripheral blood monocytes of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 71(6), pp. 1049-1054. (doi: 10.1136/annrheumdis-2011-200703) (PMID:22294632)

2010

Dale, J. and Porter, D. (2010) Optimising the strategy of care in early rheumatoid arthritis. Best Practice and Research: Clinical Rheumatology, 24(4), pp. 443-455. (doi: 10.1016/j.berh.2009.11.009)

This list was generated on Sat Oct 23 19:04:30 2021 BST.
Number of items: 11.

Articles

Daly, R. et al. (2020) Changes in plasma itaconate elevation in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation. Metabolites, 10(6), 241. (doi: 10.3390/metabo10060241) (PMID:32531990) (PMCID:PMC7344783)

Dale, J. et al. (2016) The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 17, 461. (doi: 10.1186/s12891-016-1318-y) (PMID:27829394) (PMCID:PMC5103386)

Kronisch, C. et al. (2016) Brief report: predicting functional disability: one-year results from the Scottish Early Rheumatoid Arthritis inception cohort. Arthritis and Rheumatology, 68(7), pp. 1596-1602. (doi: 10.1002/art.39627) (PMID:26866516)

Porter, D. et al. (2016) Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet, 388(10041), pp. 239-247. (doi: 10.1016/S0140-6736(16)00380-9) (PMID:27197690)

Dale, J. et al. (2016) Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Annals of the Rheumatic Diseases, 75(6), pp. 1043-1050. (doi: 10.1136/annrheumdis-2015-208941) (PMID:27026689)

Dale, J. (2015) Advances in the management of rheumatoid arthritis. Scottish Medical Journal, 60(3), pp. 108-114. (doi: 10.1177/0036933015592761) (PMID:26122283)

Dale, J., Purves, D., McConnachie, A. , McInnes, I. and Porter, D. (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care and Research, 66(1), pp. 19-26. (doi: 10.1002/acr.22218)

Porter, D., Dale, J. and Sattar, N. (2014) How low to aim in rheumatoid arthritis? Learning from other disciplines. Annals of the Rheumatic Diseases, 73(3), pp. 480-482. (doi: 10.1136/annrheumdis-2013-204339)

Crilly, A. et al. (2012) PAR2 expression in peripheral blood monocytes of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 71(6), pp. 1049-1054. (doi: 10.1136/annrheumdis-2011-200703) (PMID:22294632)

Dale, J. and Porter, D. (2010) Optimising the strategy of care in early rheumatoid arthritis. Best Practice and Research: Clinical Rheumatology, 24(4), pp. 443-455. (doi: 10.1016/j.berh.2009.11.009)

Conference or Workshop Item

Derakhshan, M. H., Morton, F., Fragoulis, G. E., Paterson, C., Dale, J., Basu, N. , Mcinnes, I., Porter, D. and Siebert, S. (2021) Opioids and analgesic use in early rheumatoid arthritis: a longitudinal analysis of linked real-world prescription data. Annals of the Rheumatic Diseases 80(S1): 1159. EULAR 2021 Virtual Congress., 2-5 June 2021. (doi:10.1136/annrheumdis-2021-eular.2672)

This list was generated on Sat Oct 23 19:04:30 2021 BST.